Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2012 March;64(1) > Minerva Urologica e Nefrologica 2012 March;64(1):19-33

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

  BASIC UROLOGY


Minerva Urologica e Nefrologica 2012 March;64(1):19-33

language: English

Prostate cancer stem cell biology

Yu C. 1, 2, Yao Z. 2, Jiang Y. 1, 2, Keller E. T. 1

1 Department of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA;
2 Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China Tianjin Medical University, Tianjin, P.R. China


PDF  


The cancer stem cell (CSC) model provides insights into pathophysiology of cancers and their therapeutic response. The CSC model has been both controversial, yet provides a foundation to explore cancer biology. In this review, we provide an overview of CSC concepts, biology and potential therapeutic avenues. We then focus on prostate CSC including 1) their purported origin as either basal-derived or luminal-derived cells; 2) markers used for prostate CSC identification; 3) alterations of signaling pathways in prostate CSCs; 4) involvement of prostate CSCs in metastasis of PCa; and 5) microRNA-mediated regulation of prostate CSCs. Although definitive evidence for the identification and characterization of prostate CSCs still remains unclear, future directions pursuing therapeutic targets of CSCs may provide novel insights for the treatment of PCa.

top of page

Publication History

Cite this article as

Corresponding author e-mail

etkeller@ umich.edu